CFF provided the following clinical trial updates on 11/30/2016:
Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis
Description: This two-part study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor. It will also look at how the body processes the drug.
Age: 6 Years to 11 Years
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40% or greater
Number of Visits: 9
Length of Participation: 28 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02953314
Phase 2 study of VX-440 combination drug in people with cystic fibrosis
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661).
Age: 18 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 11
Length of Participation: 57 days
ClinicalTrials.gov link: https://clinicaltrials.gov/show/NCT02951182
Phase 2 study of VX-152 combination drug in people with cystic fibrosis
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).
Age: 18 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 10
Length of Participation: 16 weeks
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02951195